Adobe Systems Inc vs AstraZeneca plc — how do they compare? Adobe Systems Inc trades at $260.66 (market cap $104.82B), while AstraZeneca plc trades at $157.96 (market cap $248.14B). The key difference: AstraZeneca plc is far larger — about 2.4× Adobe Systems Inc's market cap, and AstraZeneca plc pays a 2.01% dividend while Adobe Systems Inc pays none. Which is the better fit depends on your goals.
| ADBE | AZN | |
|---|---|---|
Market Cap | $104.82B | $248.14B |
Volume | 5,187,646 | — |
Sector | Technology | Health |
52-Week High | $367.46 | $209.48 |
52-Week Low | $193.41 | $147.06 |
Enterprise Value | $106.26B | $275.41B |
Dividend Yield | — | 2.01% |
Signals from Pluang's Aura AI — not financial advice
Adobe (ADBE) trades at $272.96, up 2.92% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 2025 revenue of $23.77B and net income of $7.13B, maintaining exceptional profitability margins. Recent earnings beats and accelerating revenue growth contrast with market concerns about AI competition and CEO transition.
Adobe presents a compelling value opportunity trading below analyst consensus targets despite strong operational performance. Key risks include AI disruption threats and ongoing leadership transition, while institutional accumulation and positive earnings momentum support potential upside. The stock's current valuation multiples appear attractive relative to growth prospects.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →